Norges Bank Supernus Pharmaceuticals, Inc. Transaction History

Norges Bank

  • $870 Trillion
  • Q3 2025

Shares

49 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025
BUY
$30.29 - $33.43 $951,257 - $1.05 Million
31,405 New
31,405 $989,000
Q4 2024

Feb 12, 2025
BUY
$31.89 - $37.83 $4 Million - $4.75 Million
125,551 New
125,551 $4.54 Million
Q3 2024

Nov 12, 2025
BUY
$25.77 - $35.16 $3.37 Million - $4.6 Million
130,925 Added 416.89%
162,330 $5.06 Million
Q2 2024

Aug 14, 2024
BUY
$25.99 - $33.85 $5.43 Million - $7.07 Million
208,835 New
208,835 $5.59 Million
Q1 2024

May 14, 2025
BUY
$27.11 - $35.17 $6.3 Million - $8.17 Million
232,245 New
232,245 $7.92 Million
Q4 2023

Feb 09, 2024
BUY
$22.72 - $29.68 $6.25 Million - $8.17 Million
275,140 New
275,140 $7.96 Million
Q3 2023

Nov 13, 2024
BUY
$27.57 - $32.91 $8.2 Million - $9.78 Million
297,288 New
297,288 $8.2 Million
Q3 2023

Nov 13, 2023
SELL
$27.57 - $32.91 $11.8 Million - $14.1 Million
-428,573 Closed
0 $0
Q2 2023

Aug 14, 2024
BUY
$29.91 - $38.73 $3.94 Million - $5.11 Million
131,812 Added 63.12%
340,647 $10.2 Million
Q2 2023

Aug 14, 2023
SELL
$29.91 - $38.73 $12.8 Million - $16.6 Million
-428,573 Closed
0 $0
Q1 2023

May 15, 2024
BUY
$34.93 - $42.03 $12.5 Million - $15 Million
357,100 New
357,100 $12.9 Million
Q4 2022

Feb 14, 2023
BUY
$31.09 - $37.88 $13.3 Million - $16.2 Million
428,573 New
428,573 $15.3 Million
Q3 2022

Nov 13, 2023
BUY
$28.79 - $35.41 $12.3 Million - $15.2 Million
428,573 New
428,573 $14.5 Million
Q2 2022

Aug 14, 2023
BUY
$25.33 - $34.25 $10.9 Million - $14.7 Million
428,573 New
428,573 $12.4 Million
Q1 2022

May 12, 2023
BUY
$28.51 - $32.9 $1.33 Million - $1.53 Million
46,561 Added 10.86%
475,134 $15.4 Million
Q1 2022

May 09, 2022
SELL
$28.51 - $32.9 $14.1 Million - $16.3 Million
-495,313 Closed
0 $0
Q4 2021

Mar 09, 2022
BUY
$26.37 - $34.22 $13.1 Million - $16.9 Million
495,313 New
495,313 $14.4 Million
Q3 2021

Nov 14, 2022
BUY
$23.54 - $31.39 $10.4 Million - $13.8 Million
440,650 New
440,650 $11.8 Million
Q3 2021

Nov 05, 2021
SELL
$23.54 - $31.39 $9.74 Million - $13 Million
-413,763 Closed
0 $0
Q2 2021

Aug 15, 2022
BUY
$26.72 - $33.19 $11.1 Million - $13.7 Million
413,763 New
413,763 $12.7 Million
Q2 2021

Aug 10, 2021
SELL
$26.72 - $33.19 $13 Million - $16.1 Million
-485,679 Closed
0 $0
Q1 2021

May 09, 2022
BUY
$24.15 - $31.45 $11.7 Million - $15.3 Million
485,679 New
485,679 $12.7 Million
Q1 2021

May 07, 2021
SELL
$24.15 - $31.45 $12.8 Million - $16.7 Million
-530,928 Closed
0 $0
Q4 2020

Mar 02, 2021
BUY
$17.7 - $25.81 $9.4 Million - $13.7 Million
530,928 New
530,928 $13.4 Million
Q4 2020

Feb 10, 2021
SELL
$17.7 - $25.81 $10.3 Million - $15 Million
-581,894 Closed
0 $0
Q3 2020

Nov 12, 2021
BUY
$20.2 - $25.05 $11.8 Million - $14.6 Million
581,894 New
581,894 $12.1 Million
Q3 2020

Nov 10, 2020
SELL
$20.2 - $25.05 $12.8 Million - $15.9 Million
-635,120 Closed
0 $0
Q2 2020

Aug 13, 2021
BUY
$17.09 - $24.89 $10.9 Million - $15.8 Million
635,120 New
635,120 $15.1 Million
Q2 2020

Aug 07, 2020
SELL
$17.09 - $24.89 $11.9 Million - $17.4 Million
-698,547 Closed
0 $0
Q1 2020

May 07, 2021
BUY
$14.45 - $24.69 $10.1 Million - $17.2 Million
698,547 New
698,547 $12.6 Million
Q1 2020

May 08, 2020
SELL
$14.45 - $24.69 $10.1 Million - $17.2 Million
-698,547 Closed
0 $0
Q4 2019

Mar 03, 2020
BUY
$19.93 - $29.13 $13.9 Million - $20.3 Million
698,547 New
698,547 $16.6 Million
Q4 2019

Feb 12, 2020
SELL
$19.93 - $29.13 $13.9 Million - $20.3 Million
-698,547 Closed
0 $0
Q3 2019

Nov 13, 2020
BUY
$25.47 - $33.37 $17.8 Million - $23.3 Million
698,547 New
698,547 $19.2 Million
Q3 2019

Nov 08, 2019
SELL
$25.47 - $33.37 $18.6 Million - $24.4 Million
-729,845 Closed
0 $0
Q2 2019

Aug 13, 2020
BUY
$29.96 - $38.87 $21.9 Million - $28.4 Million
729,845 New
729,845 $24.2 Million
Q2 2019

Aug 09, 2019
SELL
$29.96 - $38.87 $21.9 Million - $28.4 Million
-729,845 Closed
0 $0
Q1 2019

May 11, 2020
SELL
$32.77 - $41.99 $458,780 - $587,860
-14,000 Reduced 1.88%
729,845 $25.6 Million
Q4 2018

Mar 04, 2019
BUY
$30.84 - $49.51 $22.9 Million - $36.8 Million
743,845 New
743,845 $24.7 Million
Q4 2018

Feb 08, 2019
SELL
$30.84 - $49.51 $22.9 Million - $36.8 Million
-743,845 Closed
0 $0
Q3 2018

Nov 12, 2019
BUY
$42.7 - $56.55 $31.8 Million - $42.1 Million
743,845 New
743,845 $37.5 Million
Q3 2018

Nov 09, 2018
SELL
$42.7 - $56.55 $31.8 Million - $42.1 Million
-743,845 Closed
0 $0
Q2 2018

Aug 12, 2019
BUY
$44.1 - $59.85 $32.8 Million - $44.5 Million
743,845 New
743,845 $44.5 Million
Q2 2018

Jul 23, 2018
SELL
$44.1 - $59.85 $29.2 Million - $39.6 Million
-662,409 Closed
0 $0
Q1 2018

May 15, 2019
BUY
$37.15 - $46.9 $24.6 Million - $31.1 Million
662,409 New
662,409 $30.3 Million
Q1 2018

May 09, 2018
SELL
$37.15 - $46.9 $21.8 Million - $27.5 Million
-586,591 Closed
0 $0
Q4 2017

Mar 05, 2018
BUY
$36.4 - $42.6 $21.4 Million - $25 Million
586,591 New
586,591 $23.4 Million
Q4 2017

Feb 09, 2018
SELL
$36.4 - $42.6 $14.6 Million - $17.1 Million
-401,193 Closed
0 $0
Q3 2017

Nov 13, 2018
BUY
$36.75 - $49.65 $14.7 Million - $19.9 Million
401,193
401,193 $16 Million

Others Institutions Holding SUPN

# of Institutions
330
Shares Held
60.2M
Call Options Held
234K
Put Options Held
0
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.41B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email